{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%280.9%25+Sodium+chloride%29+infusion&page=15", "query": { "intervention": "Placebo (0.9% Sodium chloride) infusion", "page": 15 }, "page_size": 10 }, "pagination": { "page": 15, "page_size": 10, "total_count": 416, "total_pages": 42, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%280.9%25+Sodium+chloride%29+infusion&page=16&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%280.9%25+Sodium+chloride%29+infusion&page=14&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T08:06:16.186Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03240068", "title": "Angiotensin-(1-7) in Peripheral Arterial Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Peripheral Arterial Disease" ], "interventions": [ { "name": "Angiotensin 1-7", "type": "DRUG" }, { "name": "Saline", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Milton S. Hershey Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "21 Years to 80 Years" }, "enrollment_count": 6, "start_date": "2017-09-01", "completion_date": "2020-03-09", "has_results": false, "last_update_posted_date": "2024-05-03", "last_synced_at": "2026-10-14T08:06:16.186Z", "location_count": 1, "location_summary": "Hershey, Pennsylvania", "locations": [ { "city": "Hershey", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03240068" }, { "nct_id": "NCT00849667", "title": "Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ovarian Cancer" ], "interventions": [ { "name": "Farletuzumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Taxane", "type": "DRUG" }, { "name": "Farletuzumab-matched placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Morphotek", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 1100, "start_date": "2009-04-16", "completion_date": "2013-04-12", "has_results": true, "last_update_posted_date": "2022-12-30", "last_synced_at": "2026-10-14T08:06:16.186Z", "location_count": 110, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 91 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00849667" }, { "nct_id": "NCT05747924", "title": "Phase 1/2 Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "FSHD", "FSHD1", "FSHD2", "FMD", "FMD2", "Fascioscapulohumeral Muscular Dystrophy", "Fascioscapulohumeral Muscular Dystrophy Type 1", "Fascioscapulohumeral Muscular Dystrophy Type 2", "Dystrophies, Facioscapulohumeral Muscular", "Dystrophy, Facioscapulohumeral Muscular", "Facioscapulohumeral Muscular Dystrophy 1", "Facioscapulohumeral Muscular Dystrophy 2", "Facio-Scapulo-Humeral Dystrophy", "Atrophy, Facioscapulohumeral", "Atrophies, Facioscapulohumeral", "Facioscapulohumeral Atrophy", "Muscular Dystrophies", "Muscular Dystrophy, Facioscapulohumeral", "FSH Muscular Dystrophy", "Landouzy Dejerine Dystrophy", "Landouzy-Dejerine Muscular Dystrophy", "Dystrophies, Landouzy-Dejerine", "Dystrophy, Landouzy-Dejerine", "Landouzy-Dejerine Syndrome", "Muscular Dystrophy, Landouzy Dejerine", "Progressive Muscular Dystrophy", "FSH" ], "interventions": [ { "name": "AOC 1020", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Avidity Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "16 Years to 70 Years" }, "enrollment_count": 90, "start_date": "2023-04-04", "completion_date": "2026-03-20", "has_results": false, "last_update_posted_date": "2026-07-16", "last_synced_at": "2026-10-14T08:06:16.186Z", "location_count": 14, "location_summary": "Los Angeles, California • Palo Alto, California • San Diego, California + 11 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05747924" }, { "nct_id": "NCT00454818", "title": "Efficacy and Safety Study of Genetically Targeted Enzyme Replacement Therapy for Advanced Heart Failure", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Heart Failure, Congestive", "Dilated Cardiomyopathy" ], "interventions": [ { "name": "MYDICAR Phase 1 (Open-label, Serial Dose-Escalation Study)", "type": "GENETIC" }, { "name": "Placebo Infusion", "type": "PROCEDURE" }, { "name": "MYDICAR Phase 2 (Placebo-controlled, Randomized Study)", "type": "GENETIC" } ], "intervention_types": [ "GENETIC", "PROCEDURE" ], "sponsor": "Celladon Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 51, "start_date": "2007-03", "completion_date": "2012-08", "has_results": true, "last_update_posted_date": "2014-08-20", "last_synced_at": "2026-10-14T08:06:16.186Z", "location_count": 22, "location_summary": "San Diego, California • Gainesville, Florida • Chicago, Illinois + 15 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00454818" }, { "nct_id": "NCT05721287", "title": "A Phase 1, Randomized, Placebo-Controlled Safety and Tolerability Study Of Intravenous SBS-1000 in Healthy Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pain", "Acute Pain" ], "interventions": [ { "name": "SBS-1000", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sparian Biosciences, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "59 Years", "sex": "ALL", "summary": "18 Years to 59 Years" }, "enrollment_count": 48, "start_date": "2023-01-30", "completion_date": "2023-08-30", "has_results": false, "last_update_posted_date": "2025-11-26", "last_synced_at": "2026-10-14T08:06:16.186Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05721287" }, { "nct_id": "NCT05479981", "title": "Extension of AOC 1001-CS1 (MARINA) Study in Adult Myotonic Dystrophy Type 1 (DM1) Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "DM1", "Muscular Dystrophies", "Myotonic Dystrophy", "Myotonic Dystrophy 1", "Myotonic Disorders", "Muscular Disorders, Atrophic", "Muscular Diseases", "Musculoskeletal Diseases", "Neuromuscular Diseases", "Nervous System Diseases", "Genetic Diseases, Inborn", "Heredodegenerative Disorders, Nervous System", "Neurodegenerative Diseases" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "AOC 1001", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Avidity Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "66 Years", "sex": "ALL", "summary": "18 Years to 66 Years" }, "enrollment_count": 37, "start_date": "2022-08-04", "completion_date": "2025-09-10", "has_results": false, "last_update_posted_date": "2026-09-11", "last_synced_at": "2026-10-14T08:06:16.186Z", "location_count": 8, "location_summary": "Los Angeles, California • Palo Alto, California • Denver, Colorado + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Kansas City", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05479981" }, { "nct_id": "NCT06679855", "title": "Milrinone for Prevention of Post-ligation Cardiac Syndrome Trial", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Post-ligation Cardiac Syndrome" ], "interventions": [ { "name": "Milrinone infusion", "type": "DRUG" }, { "name": "Placebo infusion", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NICHD Neonatal Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "3 Months", "sex": "ALL", "summary": "Up to 3 Months" }, "enrollment_count": 316, "start_date": "2025-06-13", "completion_date": "2029-06-30", "has_results": false, "last_update_posted_date": "2026-07-01", "last_synced_at": "2026-10-14T08:06:16.186Z", "location_count": 19, "location_summary": "Birmingham, Alabama • Orange, California • Palo Alto, California + 16 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Orange", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06679855" }, { "nct_id": "NCT02481674", "title": "A Study in Subjects With Late Prodromal & Early Manifest HD to Assess the Safety, Tolerability, pk, and Efficacy of Pepi", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Huntington's Disease" ], "interventions": [ { "name": "VX15/2503", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vaccinex Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 301, "start_date": "2015-07", "completion_date": "2020-08", "has_results": false, "last_update_posted_date": "2022-05-02", "last_synced_at": "2026-10-14T08:06:16.186Z", "location_count": 29, "location_summary": "Birmingham, Alabama • La Jolla, California • San Francisco, California + 24 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02481674" }, { "nct_id": "NCT01274260", "title": "Trial of Steroids in Pediatric Acute Lung Injury/ARDS", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Respiratory Distress Syndrome (ARDS)", "Acute Lung Injury (ALI)" ], "interventions": [ { "name": "methylprednisolone", "type": "DRUG" }, { "name": "Normal Saline (0.9%)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Tennessee", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Month", "maximum_age": "18 Years", "sex": "ALL", "summary": "1 Month to 18 Years" }, "enrollment_count": 100, "start_date": "2010-10", "completion_date": "2014-12", "has_results": false, "last_update_posted_date": "2014-05-28", "last_synced_at": "2026-10-14T08:06:16.186Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01274260" }, { "nct_id": "NCT05267886", "title": "CAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic Shock", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Shock, Cardiogenic" ], "interventions": [ { "name": "Dobutamine", "type": "DRUG" }, { "name": "Milrinone", "type": "DRUG" }, { "name": "Normal Saline", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ottawa Heart Institute Research Corporation", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 346, "start_date": "2022-03-05", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-05-01", "last_synced_at": "2026-10-14T08:06:16.186Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05267886" } ] }